Skip to main
NXTC

Nextcure (NXTC) Stock Forecast & Price Target

Nextcure (NXTC) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NextCure Inc. has secured global rights to SIM0505, which could generate up to $745 million in upfront and milestone payments, alongside tiered royalties that may reach double-digit percentages on net sales, indicating strong potential revenue streams. The company is focused on adding value to its ADC programs while acknowledging the need to adjust valuations for NC410 and NC525, with a long-term outlook extending to mid-2026. Additionally, preclinical data for SIM0505 exhibits promising anti-tumor activity and a favorable safety profile, supporting the company's continued advancement in clinical trials, including a planned Phase I study in the U.S.

Bears say

NextCure Inc. has recently revised its projected enterprise value, decreasing it significantly from $75 million to $37.5 million, which reflects a concerning outlook for the company’s financial health. The substantial drop in the price target from $36 to $15 suggests a lack of confidence in achieving future milestones, particularly given the risks associated with the clinical success of its therapies. Additionally, the company is seeking partnerships for several programs, indicating potential limitations in its financial resources and ability to independently advance its drug candidates.

Nextcure (NXTC) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nextcure (NXTC) Forecast

Analysts have given Nextcure (NXTC) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Nextcure (NXTC) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nextcure (NXTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.